DOCSLIB.ORG

Seven Controversies in Psychedelic Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Seven Controversies in Psychedelic Medicine Alex Belser, PhD Co-Investigator, Yale University Founding President, Nautilus Sanctuary Chief Clinical Officer, Adelia Therapeutics Chief Clinical Advisor, Cybin Disclosures ✧ Funding Sources, last 3 years ✧ Yale University ✧ NYU School of Medicine ✧ NYU Steinhardt School of Culture, Education, and Human Development ✧ MAPS Public Benefit Corporation ✧ Adelia Therapeutics ✧ Cybin ✧ Heffter Research Institute ✧ Synthesis Institute Psychedelic Effects Psilocybin Ketamine Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651. Psychedelic Research: An overview 200 mushroom stones found in post-Mayan civilization in the Guatemala highlands Gold Pectorals from the Sinú culture of Columbia (1200 - 1600 c.e.) Psychedelic Clinical Trials: Count 1994-2020 (excludes ketamine) Web of science: psychedelic publication count by year Petranker, R., Anderson, T., & Farb, N. (2020). Psychedelic research and the need for transparency: Polishing Alice’s Looking Glass. Frontiers in psychology, 11, 1681. Psilocybin + Psychotherapy Interventions for Anxiety and Depression ✧ Meta analysis: large magnitude effect sizes ✧ Large pre-post and pre-follow-up effects on anxiety and depression ✧ Hedges’ gs =1.16 to 1.47 The Experimental Effects of Psilocybin on Symptoms of Anxiety and Depression: A Meta-analysis (Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas, Charles L. Raison, Paul R. Hutson, 2020) Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021). Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 1-14. Seven Controversies in Psychedelic Research Seven Controversies in Psychedelic Medicine #1: How do these drugs work? #2: Should psychedelic treatment be considered a combination therapy? #3: What theoretical approach should we use? #4: Do these drugs really work, or is it super placebo? #5: What credentials and scope of training should be required to facilitate a psychedelic medication session? #6: What specific training should be required to become a psychedelic-assisted psychotherapist? #7: Should psychedelic therapists in training undergo an experiential component? #1: How do these drugs work? Person takes Psychedelics Symptom reduction Observer Mechanisms of Action: 3 proposed classes 1. Neurobiological mechanisms 2. Psychological mechanisms 3. Psychospiritual/mystical mediators Neurobiological Mechanisms ✧ 5HT2A receptor downregulation ✧ Enhanced cortical glutamatergic transmission in medial PFC ✧ Increased AMPA activation ✧ Reduced DMN activity ✧ Increases in cortical and subcortical BDNF levels ✧ Learning/neuroplasticity ✧ Increased functional connectivity within a limbic/paralimbic network ✧ Anti-inflammatory mechanisms (Nichols, Charles) Psychological Mechanisms Common Factors Psychedelic-Specific Factors ✧ Therapeutic alliance ✧ Relational/attachment ✧ Empathy ✧ Emotional range ✧ Goal consensus and collaboration ✧ Embodiment ✧ Positive regard and affirmation ✧ Revised life priorities ✧ Mastery ✧ Exalted feeling of joy, bliss, or love ✧ Congruence/genuineness ✧ Ineffability ✧ Mentalization ✧ Alterations to identity during psilocybin experience ✧ Emotional experience ✧ “Bad trip” experiences of transient psychological distress Belser et al., 2017 Psychospiritual Mediators ✧ Mystical experience hypothesis → anxiety, depression, cocaine, drinking, smoking cessation Pahnke 1963; Gasser, Kirchner, and Passie, 2014; Griffiths, et al., 2006; Griffiths, et al., 2008; MacLean, Johnson, & Griffiths, 2011; Bogenschutz, et al., 2015; Studerus, Kometer, Hasler, & Vollenweider, 2011; Ross et al, 2016; Griffiths et al., 2016; Rothberg, R. L., Azhari, N., Haug, N. A., & Dakwar, E. (2020). Mystical experience is one of many mediators ✧ Only 13% of variability in depression is ✧ 35% of the variability in anxiety is explained explained by the MEQ score by the MEQ score ✧ 87% of depression improvement is ✧ 65% of anxiety decrease is attributable to attributable to other unknown other unknown mechanisms mechanisms Griffiths et al., 2016 #2: Should psychedelic treatment be considered a combination therapy or medication alone? From the first meeting, psychedelic-assisted psychotherapy builds from good rapport and a strong alliance between the clinicians and the patient to optimize set and setting. • Protocols include: 40+ hours of psychotherapy • Risk of adverse events and serious adverse events Time Intensive Combination Treatment 1. Clinician qualifications: psychotherapist and psychedelic-specific competencies 2. Extensive training to competently conduct psychedelic-assisted psychotherapy 3. Preparation psychotherapy and psychoeducation sessions 4. Psychedelic medicine administration (investigational product) psychotherapy session 5. Integration psychotherapy sessions 6. Ongoing supervision, treatment fidelity and adherence assessment What is the role of the psychotherapeutic intervention in efficacy? This unique combination treatment combines (a) a psychotherapy intervention with (b) a pharmacological intervention. This platform may provide: 1. Independent (additive) effects 2. Interactive effects 3. Enhanced effectiveness of each intervention 4. Safety as ensured by the provision of competent psychotherapy Issue of whittling down psychotherapy ✧ It’s cheaper to skimp on the psychotherapy ✧ How much prep and how much integration is really needed? ✧ Can we substitute digital therapeutics, apps, baby monitors in clinic? ✧ Removing therapy: a dismantling study would be required ✧ Ethical risks to dropping psychotherapy entirely ✧ Avoid obfuscation re: “psychedelic support” vs. “psychedelic-assisted psychotherapy” ✧ If all the research trial providers are psychiatrists, they’re probably providing psychotherapy #3: What theoretical approach should we use in psychedelic-assisted psychotherapy? ✧ Non-directive Psychotherapy Levine, ✧ Inner-directed – MAPS ✧ Internal Family Systems – Dick Schwartz ✧ Relational/psychodynamic – Jeff Guss, Raquel Bennett ✧ Couples therapy – Anne Wagner – Canada, (MDMA) & Gita Vaid ✧ Group Work ✧ CBT – Matt Johnson smoking cessation trials ✧ Family Therapy – Annie Lalla ✧ Motivational Interviewing – META – Michael ✧ Transtheoretical Psychedelic Support – Ingmar Bogenschutz Gorman & Elizabeth Nielson ✧ Acceptance and Commitment Therapy – Hexaflex ✧ Multitheoretical Psychedelic-Assisted Psychotherapy – Model – Jordan Sloshower & Jeff Guss Alex Belser & Bill Brennan ✧ Somatic practices – Bessel Van der Kolk and Peter #4: Do these drugs really work or is it super placebo? Current Approach Alternatives ✧ Problems of functional unblinding ✧ Standard of care comparator ✧ Dose response study ✧ Inert placebo comparator ✧ Active placebo comparator #5: What credentials and scope of training should be required to facilitate a psychedelic medication session? 1. Psychotherapists (including psychiatrists and “The psychological support is an psychiatric NPs with psychotherapy training) integral element of psilocybin therapy 2. Nurses and must be provided by trained therapists.” 3. Paraprofessionals ✧ Psychotherapy or pseudotherapy? – Bill Richards ✧ Competency in psychotherapy requires: Psychologist, Johns Hopkins, Lead ✧ 3,000 hours for master’s counselors Trainer, Compass Pathways ✧ 3,500 hours for psychologists ✧ Scope of practice conflicts #6: What specific training should be required to become a psychedelic-assisted psychotherapist? ✧ It’s not “see one, do one, teach one” ✧ Challenge: no current licensing infrastructure in 1. MAPS: 120 hours of training place 2. Compass Pathways: ~ 100+ hours ✧ Challenge: no standardized training 3. Center for Consciousness Medicine: 150 hour ✧ Iatrogenic risk 4. School of Consciousness Medicine: 250 hour ✧ Intersubjective work: requires experienced 5. Synthesis Institute: 18 months provider 6. Psychedelic apprenticeship (Timmerman, Watts & Dupuis, 2020) #7: Should psychedelic therapists in training undergo an experiential component? ✧ Experiential training is considered essential by senior facilitators ✧ Experiential training is considered essential in indigenous cultures that have used psychedelic medicine ✧ MAPS offers this experiential component to the training via a Phase 1 trial ✧ Current training paradigms don’t generally provide for legal experiential components (Nielson & Guss, 2018; Winkler & Csemy, 2014; Winkler, Gorman & Kočárová, 2016) Seven Controversies in Psychedelic Medicine #1: How do these drugs work? #2: Should psychedelic treatment be considered a combination therapy? #3: What theoretical approach should we use? #4: Do these drugs really work, or is it super placebo? #5: What credentials and scope of training should be required to facilitate a psychedelic medication session? #6: What specific training should be required to become a psychedelic-assisted psychotherapist? #7: Should psychedelic therapists in training undergo an experiential component? Thank You References ✧ Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L., Hui, K., . Farb, N. A. (2019). Microdosing psychedelics: Personality, mental health, and creativity differences in microdosers. Psychopharmacology. doi:10.1007/s00213-018- 5106-2 ✧ Erritzoe, D., Roseman, L., Nour, M. M., Maclean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin
Recommended publications
  • 4/23/2015 1 •Psychedelics Or Hallucinogens

    4/23/2015 1 •Psychedelics Or Hallucinogens

    4/23/2015 Hallucinogens •Psychedelics or This “classic” hallucinogen column The 2 groups below are quite different produce similar effects From the classic hallucinogens Hallucinogens Drugs Stimulating 5HT Receptors Drugs BLOCKING ACH Receptors • aka “psychotomimetics” LSD Nightshade(Datura) Psilocybin Mushrooms Jimsonweed Morning Glory Seeds Atropine Dimethyltryptamine Scopolamine What do the very mixed group of hallucinogens found around the world share in common? •Drugs Resembling NE Drugs BLOCKING Glutamate Receptors •Peyote cactus Phencyclidine (PCP) •Mescaline Ketamine All contain something that resembles a •Methylated amphetamines like MDMA High dose dextromethorphan •Nutmeg neurotransmitter •New synthetic variations (“bath salts”) •5HT-Like Hallucinogens •LSD History • Serotonin • created by Albert Hofmann for Sandoz Pharmaceuticals LSD • was studying vasoconstriction produced by ergot alkaloids LSD • initial exposure was accidental absorption thru skin • so potent ED is in millionths of a gram (25-250 micrograms) & must be delivered on something else (sugar cube, gelatin square, paper) Psilocybin Activate 5HT2 receptors , especially in prefrontal cortex and limbic areas, but is not readily metabolized •Characteristics of LSD & Other “Typical” •Common Effects Hallucinogens • Sensory distortions (color, size, shape, movement), • Autonomic (mostly sympathetic) changes occur first constantly changing (relatively mild) • Vivid closed eye imagery • Sensory/perceptual changes follow • Synesthesia (crossing of senses – e.g. hearing music
  • Hallucinogens - LSD, Peyote, Psilocybin, and PCP

    Hallucinogens - LSD, Peyote, Psilocybin, and PCP

    Information for Behavioral Health Providers in Primary Care Hallucinogens - LSD, Peyote, Psilocybin, and PCP What are Hallucinogens? Hallucinogenic compounds found in some plants and mushrooms (or their extracts) have been used— mostly during religious rituals—for centuries. Almost all hallucinogens contain nitrogen and are classified as alkaloids. Many hallucinogens have chemical structures similar to those of natural neurotransmitters (e.g., acetylcholine-, serotonin-, or catecholamine-like). While the exact mechanisms by which hallucinogens exert their effects remain unclear, research suggests that these drugs work, at least partially, by temporarily interfering with neurotransmitter action or by binding to their receptor sites. This InfoFacts will discuss four common types of hallucinogens: LSD (d-lysergic acid diethylamide) is one of the most potent mood-changing chemicals. It was discovered in 1938 and is manufactured from lysergic acid, which is found in ergot, a fungus that grows on rye and other grains. Peyote is a small, spineless cactus in which the principal active ingredient is mescaline. This plant has been used by natives in northern Mexico and the southwestern United States as a part of religious ceremonies. Mescaline can also be produced through chemical synthesis. Psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) is obtained from certain types of mushrooms that are indigenous to tropical and subtropical regions of South America, Mexico, and the United States. These mushrooms typically contain less than 0.5 percent psilocybin plus trace amounts of psilocin, another hallucinogenic substance. PCP (phencyclidine) was developed in the 1950s as an intravenous anesthetic. Its use has since been discontinued due to serious adverse effects. How Are Hallucinogens Abused? The very same characteristics that led to the incorporation of hallucinogens into ritualistic or spiritual traditions have also led to their propagation as drugs of abuse.
  • Psilocybin Mushrooms Fact Sheet

    Psilocybin Mushrooms Fact Sheet

    Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses.
  • Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters

    Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters

    Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant.
  • Psychedelic Agents

    Psychedelic Agents

    PSYCHEDELIC AGENTS: CHANGES INDUCED IN SUBJECTIVE EXPERIENCE AND BRAIN ACTIVITY Bachelor Degree Project in Cognitive Neuroscience Basic level 22.5 ECTS Spring term 2019 Louise Andersson Supervisor: Katja Valli Examiner: Joel Parthemore Abstract This thesis combines phenomenological and neuroscientific research to elucidate the effects of psychedelic agents on the human brain, mind and psychological well-being. Psychoactive plants have been used for thousands of years for ceremonial and ritual purposes. Psychedelics are psychoactive substances that affect cognitive processes and alter perception, thoughts, and mood. Illegalization of psychedelics in the 1960s rendered them impossible to study empirically but in the last couple of decades, relaxed legal restrictions regarding research purposes, renewed interest in the effects of psychedelic drugs and new brain imaging techniques have started to reveal the possibilities of these mind-altering substances. Psychedelics mainly affect the serotonin receptor 5-HT2A which in turn affects the functioning of largescale cortical areas by changing cerebral blood flow, alpha oscillations and functional connectivity. These cortical changes not only induce immediate alterations in perception and cognition but have been shown to have positive effects in therapeutic interventions for depression, anxiety, and addiction, and also positively affect well-being in general. Although the pharmacology and neurobiology of psychedelics are still poorly understood, the potential benefits justify empirical research
  • Mushroom Pioneers

    Mushroom Pioneers

    Mushroom Pioneers by John W. Allen © 2002 by John W. Allen original source: https://www.erowid.org/library/books_online/mushroom_pioneers/mushroom_pioneers2.shtml Books by John W. Allen Magic Mushrooms of the Pacific Northwest Magic Mushrooms of the Hawaiian Islands Teonanácatl: Ancient and Contemporary Shamanic Mushroom Names of Mesoamerica and Other Regions of the World Magic Mushrooms in Some Third World Countries,co-authored by Jochen Gartz, Ph.D. CD-ROMS Teonanácatl: A Bibliography of Entheogenic Mushrooms, co-authored by Jochen Gartz, Ph.D. Psilocybian Mushroom Cultivation, co-Authored by Jochen Gartz, Ph.D. Special Thanks Jonathan Ott, Larry Zoumas and Ken Thompkins soma rights re-served 1 since 23.11.2015 at http://www.en.psilosophy.info/ mushroom pioneers www.en.psilosophy.info/nhyafuitbfizbqcicpazbdjm Ethnomycological Journals Sacred Mushrooms Studies Volume V11 Copyright@ 2002 by John W. Allen Book Cover Design by John W. Allen http://mushroomjohn.com Mushroom Pioneers at MushroomJohn.com Printed in the United States Table of Contents: Information about Online Edition Dedication Endorsement Blurbs for Mushroom Pioneers Foreword Introduction The Spanish, The Aztecs and the Sacred Fungi Chapter 1. Modern Field Research on Teonanácatl 1915-1940 Chapter 2. Richard Evans Schultes Chapter 3. Rolf Singer and the Misidentification of Teonanácatl Chapter 4. The Rediscovery of Entheogenic Mushrooms Wasson's First Voyage Wasson Meets María Sabina CIA Mole James Moore - Spies on Wasson in the Search for Mind-Control Drugs Chapter 5. María Sabina Saint Mother of the Sacred Mushrooms Childhood The Coming of the Foreigners May the Force be With You Notes Chapter 6. Albert Hofmann and the Synthesis of Psilocybine and Psilocine Chapter 7.
  • A Social and Cultural History of the Federal Prohibition of Psilocybin

    A Social and Cultural History of the Federal Prohibition of Psilocybin

    A SOCIAL AND CULTURAL HISTORY OF THE FEDERAL PROHIBITION OF PSILOCYBIN A Dissertation presented to the Faculty of the Graduate School at the University of Missouri-Columbia In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy by COLIN WARK Dr. John F. Galliher, Dissertation Supervisor AUGUST 2007 The undersigned, appointed by the dean of the Graduate School, have examined the dissertation entitled A SOCIAL AND CULTURAL HISTORY OF THE FEDERAL PROHIBITION OF PSILOCYBIN presented by Colin Wark, a candidate for the degree of doctor of philosophy and hereby certify that, in their opinion, it is worthy of acceptance. Professor John F. Galliher Professor Wayne H. Brekhus Professor Jaber F. Gubrium Professor Victoria Johnson Professor Theodore Koditschek ACKNOWLEDGEMENTS The author would like to thank a group of people that includes J. Kenneth Benson, Wayne Brekhus, Deborah Cohen, John F. Galliher, Jay Gubrium, Victoria Johnson, Theodore Koditschek, Clarence Lo, Kyle Miller, Ibitola Pearce, Diane Rodgers, Paul Sturgis and Dieter Ullrich. ii TABLE OF CONTENTS ACKNOWLEDGEMENTS ................................................................................................ ii NOTE ON TERMINOLOGY ............................................................................................ iv Chapter 1. INTRODUCTION…………………………………………………………………1 2. BIOGRAPHICAL OVERVIEW OF THE LIVES OF TIMOTHY LEARY AND RICHARDALPERT…………………………………………………….……….20 3. MASS MEDIA COVERAGE OF PSILOCYBIN AS WELL AS THE LIVES OF RICHARD ALPERT AND TIMOTHY
  • Psilocybin Fast Facts

    Psilocybin Fast Facts

    What is psilocybin? Who abuses psilocybin? In addition to the risks associated with ingestion of psilocybin, individuals Psilocybin is a hallucinogenic sub- Psilocybin mushrooms are popular at who seek to abuse psilocybin mush- stance obtained from certain types of raves, clubs and, increasingly, on rooms also risk poisoning if one of the mushrooms that are indigenous to college campuses and generally are many varieties of poisonous mush- tropical and subtropical regions of abused by teenagers and young adults. rooms is incorrectly identified as a South America, Mexico, and the It is difficult to gauge the extent of psilocybin mushroom. United States. These mushrooms psilocybin use in the United States typically contain 0.2 to 0.4 percent because most data sources that quan- What is psilocybin called? psilocybin and a trace amount of tify drug use exclude psilocybin. The psilocyn, another hallucinogenic sub- Monitoring the Future Survey, con- The most common names for stance. Both psilocybin and psilocyn ducted by the University of Michigan, psilocybin are magic mushroom, can be produced synthetically, but law does reveal that 9.2 percent of high mushroom, and shrooms. (Please enforcement reporting currently does school seniors in the United States see the Street Terms text box for not indicate that this is occurring. used hallucinogens other than LSD—a additional names.) category that includes psilocybin—at What does psilocybin look like? least once in their lifetime. Two percent of high school seniors used hallucino- Mushrooms containing psilocybin gens other than LSD in the past month. are available fresh or dried and have Street Terms for Psilocybin long, slender stems topped by caps Whatare therisks? with dark gills on the underside.
  • Hallucinogens • LSD (D-Lysergic Acid Diethylamide) Is One of the Most Potent Mood- Changing Chemicals

    Hallucinogens • LSD (D-Lysergic Acid Diethylamide) Is One of the Most Potent Mood- Changing Chemicals

    Kiara Draper & Gaby Grabowski 4 types of hallucinogens • LSD (d-lysergic acid diethylamide) is one of the most potent mood- changing chemicals. It was discovered in 1938 and is manufactured from lysergic acid, which is found in ergot, a fungus that grows on rye and other grains. • Peyote is a small, spineless cactus in which the principal active ingredient is mescaline. This plant has been used by natives in northern Mexico and the southwestern United States as a part of religious ceremonies. Mescaline can also be produced through chemical synthesis. 4 types of hallucinogens continued Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is obtained from certain types of mushrooms that are indigenous to tropical and subtropical regions of South America, Mexico, and the United States. These mushrooms typically contain less than 0.5 percent psilocybin plus trace amounts of psilocin, another hallucinogenic substance. PCP (phencyclidine) was developed in the 1950s as an intravenous anesthetic. Its use has since been discontinued due to serious adverse effects How these hallucinogens are used/abused LSD is sold in tablets, capsules, and, occasionally, liquid form; thus, it is usually taken orally. LSD is often added to absorbent paper, which is then divided into decorated pieces, each equivalent to one dose. The experiences, often referred to as “trips,” are long; typically, they end after about 12 hours. Peyote: The top of the peyote cactus, also referred to as the crown, consists of disc-shaped buttons that are cut from the roots and dried. These buttons are generally chewed or soaked in water to produce an intoxicating liquid.
  • From Recreational to Sacramental: Observing Past Entheogenic Practices and Considering Their Potential Application in the Future of Christianity

    From Recreational to Sacramental: Observing Past Entheogenic Practices and Considering Their Potential Application in the Future of Christianity

    Digital Commons @ George Fox University Doctor of Ministry Theses and Dissertations 2-2021 From Recreational to Sacramental: Observing Past Entheogenic Practices and Considering Their Potential Application in the Future of Christianity Heath Hollensbe Follow this and additional works at: https://digitalcommons.georgefox.edu/dmin Part of the Christianity Commons GEORGE FOX UNIVERSITY FROM RECREATIONAL TO SACRAMENTAL: OBSERVING PAST ENTHEOGENIC PRACTICES AND CONSIDERING THEIR POTENTIAL APPLICATION IN THE FUTURE OF CHRISTIANITY A DISSERTATION SUBMITTED TO THE FACULTY OF PORTLAND SEMINARY IN CANDIDACY FOR THE DEGREE OF DOCTOR OF MINISTRY BY HEATH HOLLENSBE PORTLAND, OREGON FEBRUARY 2021 Portland Seminary George Fox University Portland, Oregon CERTIFICATE OF APPROVAL ________________________________ DMin Dissertation ________________________________ This is to certify that the DMin Dissertation of Heath Hollensbe has been approved by the Dissertation Committee on February 17, 2021 for the degree of Doctor of Ministry in Semiotics, Church, and Culture. Dissertation Committee: Primary Advisor: Karen Claassen, DMin Secondary Advisor: David McDonald, DMin Lead Mentor: Leonard I. Sweet, PhD Expert Advisor: Karen Claassen, DMin Copyright © 2021 by Heath Hollensbe. All rights reserved. ii Table of Contents GLOSSARY ....................................................................................................................... V ABSTRACT ....................................................................................................................
  • The Pharmacology of Psilocybin

    The Pharmacology of Psilocybin

    Addiction Biology (2002) 7, 357–364 INVITED REVIEW The pharmacology of psilocybin TORSTEN PASSIE, JUERGEN SEIFERT, UDO SCHNEIDER & HINDERK M. EMRICH Department of Clinical Psychiatry and Psychotherapy, Medical School Hannover, Hannover, Germany Abstract Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamin e) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin. Introduction pharmacodynamic data of psilocybin were Psilocybin-containing mushrooms are one of the explored further.5–10 Because of the widely dis- major hallucinogenic drugs of abuse today. These persed material about the pharmacological prop- mushroom species are distributed worldwide1 erties of psilocybin, old and new data are and their abuse potential produces partially reviewed here. It should be noted that character- harmful effects in a growing population of psy- ization of the complex psychopathological phe- chedelic drug users.2 No physical damage but nomena inudced is not in the focus of this many psychiatric complications have been repor- review. ted worldwide.3 Recent research has been repor- ted on the treatment of compulsive disorders in humans with psilocybin;4 therefore, it is impor- Pharmacology of psilocybin tant to know the essential pharmacological data Psilocybin (4-phosphoryloxy-N,N-dimethyltryp- about psilocybin. tamine) is a substituted indolealkylamine and Despite the fact that pure synthetic psilocybin belongs to the group of hallucinogenic trypta- (Indocybin® Sandoz) was used and marketed for mines.
  • The Therapeutic Potential of Psilocybin

    The Therapeutic Potential of Psilocybin

    molecules Review The Therapeutic Potential of Psilocybin Henry Lowe 1,2,3,4, Ngeh Toyang 2,3 , Blair Steele 1,*, Henkel Valentine 1, Justin Grant 1,5, Amza Ali 1,5, Wilfred Ngwa 6 and Lorenzo Gordon 7 1 Biotech R & D Institute, University of the West Indies, Mona 99999, Jamaica; [email protected] (H.L.); [email protected] (H.V.); [email protected] (J.G.); [email protected] (A.A.) 2 Vilotos Pharmaceuticals Inc., Baltimore, MD 21202, USA; ngeh.toyang@flavocure.com 3 Flavocure Biotech Inc., Baltimore, MD 21202, USA 4 Institute of Human Virology (IHV), University of Maryland School of Medicine, Baltimore, MD 21202, USA 5 The Psyence Group, Toronto, ON M5J 2J1, Canada 6 Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; [email protected] 7 Caribbean School of Medical Sciences, Kingston 99999, Jamaica; [email protected] * Correspondence: [email protected]; Tel.: +876-926-8502 Abstract: The psychedelic effects of some plants and fungi have been known and deliberately ex- ploited by humans for thousands of years. Fungi, particularly mushrooms, are the principal source of naturally occurring psychedelics. The mushroom extract, psilocybin has historically been used as a psychedelic agent for religious and spiritual ceremonies, as well as a therapeutic option for neuropsychiatric conditions. Psychedelic use was largely associated with the “hippie” counterculture movement, which, in turn, resulted in a growing, and still lingering, negative stigmatization for psychedelics. As a result, in 1970, the U.S. government rescheduled psychedelics as Schedule 1 drugs, ultimately ending scientific research on psychedelics.